---
layout: default
title: Alpha -Tocopherol Succinate D- Ascorbic Acid Chole
parent: 僅模型預測 (L5)
nav_order: 250
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Succinate D- Ascorbic Acid Chole
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multivitamin Combination (B1/B2/B3/B6/B9/B12 + C + D3 + E): No Repurposing Prediction Available

## One-Sentence Summary

This product is a nine-component vitamin combination — Thiamine Mononitrate (B1), Riboflavin 5'-Phosphate (B2), Niacinamide (B3), Pyridoxine HCl (B6), Folic Acid (B9), Methylcobalamin (B12), Ascorbic Acid (C), Cholecalciferol (D3), and D-alpha-Tocopherol Succinate (E) — classically used as nutritional supplementation.
The TxGNN model returned **no predicted indications** for this combination, as the multi-ingredient formulation could not be resolved to a single DrugBank entity required for prediction.
There is currently **insufficient computational and regulatory data** to support a repurposing evaluation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Nutritional supplementation (B-complex + vitamins C, D3, E) |
| Predicted New Indication | None — TxGNN returned no candidates |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — no predictions generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

This combination contains nine distinct active ingredients across two vitamin classes: water-soluble vitamins (B1, B2, B3, B6, B9, B12, C) and fat-soluble vitamins (D3, E). Each component carries a distinct mechanism — for example, B-vitamins serve as enzyme cofactors in energy metabolism and one-carbon cycling, Vitamin D3 regulates calcium homeostasis and immune modulation, and Vitamin E acts as a lipid-soluble antioxidant. As a combined formulation, however, the product does not map to any single DrugBank identifier.

The TxGNN model operates on individual drug entities identified by DrugBank IDs. Because this formulation is a multi-ingredient combination with no unified DrugBank mapping, the model was unable to generate repurposing predictions. This is a known limitation of graph-based drug repurposing models when applied to fixed-dose combinations — the knowledge graph cannot represent the combined pharmacology as a single node.

Individual components of this combination have established evidence for repurposing investigation in separate contexts (e.g., Vitamin D in autoimmune disease, Methylcobalamin in neuropathy). However, evaluating them as a single combined entity computationally is not feasible without decomposition into constituent ingredients and re-running the pipeline per component.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline produced no output for this combination because the multi-ingredient formulation cannot be resolved to a single DrugBank node; repurposing analysis for the combination as a unified entity is therefore not currently possible.

**To proceed, the following is needed:**

- **Decompose the combination:** Run TxGNN individually on each of the nine active ingredients using their respective DrugBank IDs (e.g., DB00162 for Vitamin D3, DB00126 for Ascorbic Acid, DB01402 for Methylcobalamin, etc.)
- **Identify the primary indication:** Clarify whether this formulation targets a specific population or condition (e.g., pregnancy supplementation, post-surgical recovery, oncology supportive care), which would scope any repurposing analysis
- **Regulatory data retrieval:** Obtain package insert from the originating country to establish the approved indication and any safety warnings
- **DrugBank mapping:** Confirm DrugBank IDs for all nine ingredients to enable evidence collection via PubMed and ClinicalTrials.gov per component
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

